Aptose Biosciences Inc.

All Poster Presentation

August 21, 2025 Presentation

TUS Triplet TUSCANY Trial Update - August 2025

View Presentation

June 12, 2025 Presentation

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

View Presentation

May 5, 2025 Presentation

Aptose Corporate Presentation - Bloom Burton Conference

View Presentation

March 11, 2025 Presentation

Aptose Corporate Presentation March 2025

View Presentation

January 13, 2025 Presentation

Aptose Corporate Presentation January 2025

View Presentation

December 9, 2024 Poster

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

View Poster

November 7, 2024 Presentation

Aptose Corporate Presentation November 2024

View Presentation

July 26, 2024 Presentation

Aptose Corporate Presentation July 2024

View Presentation

June 14, 2024 Poster

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax

View Poster

1
2
3
4
5
6
7
8
9
Next